| XLS |
|
|
|
| ||
|
€ million |
Jan.–Sept. |
Jan.–Sept. | ||
| ||||
|
Profit after tax |
303.3 |
481.9 | ||
|
Depreciation/amortization/impairment losses/write-ups |
1,037.4 |
1,253.5 | ||
|
Changes in inventories |
93.4 |
–87.5 | ||
|
Changes in trade accounts receivable |
139.3 |
–74.7 | ||
|
Changes in trade accounts payable |
192.1 |
–74.3 | ||
|
Changes in provisions |
550.9 |
22.7 | ||
|
Changes in other assets and liabilities |
–216.8 |
–121.7 | ||
|
Neutralization of gain/loss on disposals of assets |
–32.0 |
–205.7 | ||
|
Other non-cash income and expenses |
6.1 |
22.6 | ||
|
Net cash flows from operating activities |
2,073.9 |
1,216.7 | ||
|
|
|
| ||
|
Purchase of intangible assets |
–88.0 |
–35.8 | ||
|
Purchase of property, plant and equipment |
–181.1 |
–246.0 | ||
|
Acquisitions |
–4.1 |
–84.3 | ||
|
Investments in financial assets |
–14.6 |
–6.5 | ||
|
Disposal of non-current assets |
63.6 |
557.3 | ||
|
Purchase/sale of marketable securities |
10.5 |
–21.3 | ||
|
Changes in other financial assets |
–370.8 |
–912.0 | ||
|
Net cash flows from investing activities |
–584.4 |
–748.6 | ||
|
|
|
| ||
|
Dividend payments |
–102.2 |
–84.5 | ||
|
Profit transfers to E. Merck KG and changes in reserves |
–92.1 |
–233.0 | ||
|
Changes in liabilities to E. Merck KG |
–143.2 |
81.5 | ||
|
Repayment of bonds |
–500.0 |
– | ||
|
Changes in current and non-current financial liabilities |
–106.2 |
–37.6 | ||
|
Net cash flows from financing activities |
–943.7 |
–273.6 | ||
|
|
|
| ||
|
Changes in cash and cash equivalents |
545.7 |
194.5 | ||
|
Changes in cash and cash equivalents due to currency translation |
1.3 |
–2.2 | ||
|
Cash and cash equivalents as of January 1 (Group balance sheet) |
937.8 |
943.7 | ||
|
Plus cash and cash equivalents previously in assets held for sale |
– |
1.2 | ||
|
Cash and cash equivalents as of September 30 |
1,484.7 |
1,137.2 | ||